An Open-label, Multicenter, Phase 1b Study of OV-1001 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination with Background Therapy for the Treatment of Subjects with Acute Myeloid Leukemia

2024-513276-17-00 Protocol ELEV20235 Human pharmacology (Phase I) - Other Ongoing, recruitment ended

Start 1 Jul 2020 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 3 sites · Protocol ELEV20235

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruitment ended
Participants planned 50
Countries 1
Sites 3

Acute Myeloid Leukemia

Key facts

Sponsor
OncoVerity Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
1 Jul 2020 → ongoing
Decision date (initial)
2024-07-22
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-513276-17-00
EudraCT number
2019-002808-41

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Acute Myeloid Leukemia

VersionLevelCodeTermSystem organ class
21.0 LLT 10000886 Acute myeloid leukemia 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

OncoVerity Inc.

Sponsor organisation
OncoVerity Inc.
Address
12635 East Montview Boulevard
City
Aurora
Postcode
80045-7335
Country
United States

Scientific contact point

Organisation
OncoVerity Inc.
Contact name
OncoVerity Help Desk

Public contact point

Organisation
OncoVerity Inc.
Contact name
OncoVerity Help Desk

Locations

1 EU/EEA country · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ongoing, recruitment ended 10 3
Rest of world
Switzerland, United States, Canada
40

Investigational sites

Germany

3 sites · Ongoing, recruitment ended
Universitaetsklinikum Leipzig AöR
Department of hematology, cell therapy and Hemostaseology, Johannisallee 32a, Zentrum-Suedost, Leipzig
University Medical Center Hamburg-Eppendorf
Internal medicine, Martinistrasse 52, Eppendorf, Hamburg
Klinikum der Universitaet Muenchen AöR
Gene Center Laboratory for Translational Cancer Immunology, Marchioninistrasse 15, Hadern, Munich

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2020-07-01 2020-08-11 2020-12-13

Application history

6 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-05 Germany Acceptable with conditions
2024-07-17
2024-07-22
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-08-07 Germany Acceptable with conditions
2024-07-17
2024-08-07
3 NON SUBSTANTIAL MODIFICATION NSM-2 2024-11-07 Germany Acceptable with conditions
2024-07-17
2024-11-07
4 SUBSTANTIAL MODIFICATION SM-1 2024-12-12 Germany Acceptable with conditions 2025-01-17
5 NON SUBSTANTIAL MODIFICATION NSM-3 2025-04-29 Germany Acceptable with conditions 2025-04-29
6 NON SUBSTANTIAL MODIFICATION NSM-4 2026-05-14 Germany Acceptable with conditions 2026-05-14